Sergej Konoplev

Also affiliated with Harrison Medical Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: a phase 1b/2 clinical trial and correlative analyses

Nature Cancer(2024)10.1038/s43018-024-00811-3

N/A

0.878DataRank · unranked

37 citations

Divij Verma, Natalia Baran, Tushar D. Bhagat, Anna Skwarska, Alessia Lodi +42 more

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses

Research Square(2023)10.21203/rs.3.rs-2518774/v1

N/A

0.312DataRank · unranked

7 citations

Courtney D. DiNardo, Tushar D. Bhagat, Natalia Baran, Alessia Lodi, Kapil Saxena +38 more

Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells

Nature Communications(2022)10.1038/s41467-022-29669-8

N/A

0DataRank · unranked

43 citations

Agnès Gouble, Kathryn L. Black, Anna Skwarska, Ammar S. Naqvi, Deanne Taylor +28 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0DataRank · unranked

174 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro

Biochemical Pharmacology(2023)10.1016/j.bcp.2023.115981

N/A

0DataRank · unranked

18 citations

Yongwei Su, Shraddha Patel, Cassandra L. Ramage, Jianlei Zhao, Brianna R. Temby +24 more

Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and purine biosynthesis

Research Square(2023)10.21203/rs.3.rs-2843025/v1

N/A

0DataRank · unranked

2 citations

Katie Hege-Hurrish, Yongwei Su, Shraddha Patel, Cassandra L. Ramage, Jenna L. Carter +22 more

Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the European LeukemiaNet adverse risk classification

American Journal of Hematology(2022)10.1002/ajh.26451

N/A

0DataRank · unranked

23 citations

Koji Sasaki, Hagop M. Kantarjian, Naval Daver, Musa Yılmaz, Courtney D. DiNardo +13 more

Inhibition of Oxidative Phosphorylation Reverses Bone Marrow Hypoxia Visualized in Imageable Syngeneic B-ALL Mouse Model

Frontiers in Oncology(2020)10.3389/fonc.2020.00991

N/A

0DataRank · unranked

18 citations

Karine G. Harutyunyan, Natalia Baran, Saradhi Mallampati, Malgorzata Anna Zal, Antonio Cavazos +9 more

Activation of RAS/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia

Signal Transduction and Targeted Therapy(2022)10.1038/s41392-021-00870-3

N/A

0DataRank · unranked

186 citations

Bridget Riley‐Gillis, Lina Han, Yannan Jia, Alessia Lodi, Haijiao Zhang +36 more